Adverum Biotechnologies

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

- ADVM-062 is designed as a potential treatment for blue cone monochromacy (X-linked incomplete achromatopsia) - - ADVM-062 is designed as a potential treatment for blue cone monochromacy (X-linked incomplete achromatopsia) -

Adverum Biotechnologies Granted Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy

Adverum Biotechnologies Inc (NASDAQ: ADVM) plans to conduct a Phase 2 trial of ADVM-022 in wet AMD at 2 X 10^11 vg/eye dose and a new lower 6 X 10^10 vg/eye dose, with three new enhanced steroid prophylaxis regimens in wet age-related macular degeneration (wet AMD).  The enhanced steroid prophylaxis regimens include topical, intravitreal (IVT), and a combination of systemic and local steroids.

Adverum Outlines Development Plan For ADVM-022 Gene Therapy In Wet AMD

- Finalizing Two-Dose Study Design for Phase 2 Trial of ADVM-022 in Wet AMDwith Intention to Dose First Patient in Q32022 -

Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022

Aterian

NuZee, Inc.

TOMI Environmental Solutions

4 penny stocks with high short interest or low floats to watch this week The post 4 Short Squeeze Penny Stocks To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Short Squeeze Penny Stocks To Watch Right Now

REDWOOD CITY, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Rupert D'Souza, Ph.D., M.B.A., has joined Adverum as the company's chief financial officer (CFO). Dr. D'Souza will serve as a member of Adverum's executive committee and will report to Laurent Fischer M.D., president and chief executive officer at Adverum Biotechnologies. Dr. D'Souza will provide leadership for the company's financial operations and planning, accounting, procurement, and select other functions.

Adverum Biotechnologies Appoints Rupert D'Souza, Ph.D., M.B.A. as Chief Financial Officer

New York, New York--(Newsfile Corp. - November 30, 2021) - Moore Kuehn, PLLC, a securities law firm located on Wall Street , is investigating whether certain officers and directors of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.If you own ADVM please contact Justin Kuehn, Esq. by email at jkuehn@moorekuehn.com or telephone at (212) 709-8245. ...

Moore Kuehn, PLLC Encourages Investors of Adverum Biotechnologies, Inc. to Contact Law Firm

REDWOOD CITY, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today reported financial results for the third quarter ending September 30, 2021 and provided a business update.

Adverum Reports Third Quarter 2021 Results

Arbutus Biopharma

Aditxt Inc

Ameri Holdings

Evofem Biosciences Inc

Are these 10 penny stocks on your watch list this week? The post Best Penny Stocks To Buy This Week?

Best Penny Stocks To Buy This Week? 10 With Potential Biotech Catalysts

-- Company maintains focus on advancing ADVM-022 at low doses in patients with wet AMD -- -- Company maintains focus on advancing ADVM-022 at low doses in patients with wet AMD --

Adverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific Meeting

Adverum Biotechnologies Inc (NASDAQ: ADVM) announced new long-term data from the OPTIC trial of ADVM-022 gene therapy for neovascular or wet age-related macular degeneration (wet AMD). Data were shared at the Retina Society's Annual Scientific Meeting.

Adverum's Single Dose Wet AMD Gene Therapy Shows Robust Two Year Durability, Safety

The stock price of Adverum Biotechnologies, Inc. (Nasdaq: ADVM) increased by over 10% pre-market today. This is why it happened.

ADVM Stock: Why It Increased Today

Kaleido Biosciences Inc

MannKind

Trevena

Will upcoming events mean big things for these penny stocks? The post 5 Penny Stocks To Watch This Week With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Watch This Week With Potential Biotech Catalysts

-- Results featured in a presentation today at the Retina Society's 54 th Annual Scientific Meeting -- -- Robust aflibercept protein expression sustained through 2 years --

Adverum Presents 2-Year OPTIC Data Demonstrating Sustained Durability and Promising Safety Profile from Single Intravitreal Injection of ADVM-022 in Wet AMD Patients Who Previously Required Frequent Anti-VEGF Injections

REDWOOD CITY, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of new clinical data on ADVM-022 intravitreal (IVT) injection gene therapy from the OPTIC trial in wet age-related macular degeneration (wet AMD) and the INFINITY trial in diabetic macular edema (DME) at upcoming medical conferences. Adverum is planning clinical development of ADVM-022 at the 2 x 10^11 vg/eye and a lower dose in patients with wet AMD. As previously disclosed, the company is no longer planning to develop ADVM-022 in DME.

Adverum to Present Data from ADVM-022 Clinical Trials at Upcoming Medical Conferences

REDWOOD CITY, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Jim Wang, Ph.D., has been appointed senior vice president, head of regulatory affairs. Reporting directly to Laurent Fischer, M.D., Adverum's president and chief executive officer, Dr. Wang will lead regulatory strategies and execution for the company's product pipeline. He brings more than 17 years of global regulatory experience, including a decade in gene therapy that includes the submission and approval for LUXTURNA®, the first gene therapy targeting a genetic disease that received regulatory approval in both the U.S. and EU.

Adverum Appoints Global Regulatory Leader Jim Wang, Ph.D., as Senior Vice President, Head of Regulatory Affairs

Adverum Biotechnologies (ADVM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Adverum Biotechnologies (ADVM) Might Surprise This Earnings Season

-- Based on latest analyses, company is revising ADVM-022 development plan to focus on  wet AMD and low doses (2 x 10^11 vg/eye and lower);  no longer planning development for DME -- -- Company to host conference call and webcast today at 1:30 pm PT / 4:30 pm ET --

Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema

Adverum Biotechnologies (ADVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Adverum Biotechnologies (ADVM) Moves to Buy: Rationale Behind the Upgrade

-- Christopher J. DeRespino appointed acting CFO -- -- Peter Soparkar appointed COO --

Adverum Announces Changes to Management Team

Caladrius Biosciences

InflaRx

There are some investors who invest in U.S.-listed stocks that are trading below their liquidation values because they believe they can gain from these allocations after the market has reappraised the share prices to near or above the liquidation value.

A Trio of Net Current Asset Value Stock Picks

The uncertainty over the biotech's lead clinical asset weighed on its shares last month.

Why Adverum Biotechnologies Stock Sank in May

Investors need to pay close attention to Adverum (ADVM) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Adverum (ADVM) Stock?

Adverum Biotechnologies (ADVM) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

Adverum Biotechnologies (ADVM) is Oversold: Can It Recover?

Infinera

Kosmos Energy

Southwestern Energy

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Goldman Sachs Has 5 Tempting Stocks Trading Under $10 to Buy Now

HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or “Adverum”), today issued the following statement regarding the preliminary voting results from the Company's 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”). “We wish to express our sincere gratitude to the stockholders who supported our push for change and an improved Board at A

News for Adverum Biotechnologies Stock (ADVM)